Pushing boundaries in mutant calreticulin-driven disease

Damora Therapeutics is building a potentially best‑in‑class portfolio of mutant calreticulin (mutCALR) targeted therapeutics to transform the treatment of mutCALR‑driven myeloproliferative neoplasms (MPNs), including essential thrombocythemia (ET) and myelofibrosis (MF).

MPNs are a group of chronic blood disorders characterized by the overproduction of blood cells in the bone marrow, and approximately 25% of ET and 35% of MF cases are driven by mutations in calreticulin. Targeting mutant calreticulin offers hope that truly disease‑modifying options may be on the horizon for patients.

Our anti‑mutCALR programs are designed to redefine the standard‑of‑care for these diseases.